Podcasts about Novo Nordisk

As Ghislaine Maxwell refuses to answer questions from Congress, federal files reveal a new characterization of how much Donald Trump knew about Jeffrey Epstein's misdeeds. Cuba tells airlines they won't be able to refuel in Havana, as US sanctions lead to an oil shortage. And drugmaker Novo Nordisk sues compound pharmacy Hims & Hers over copied weight loss drugs.  Learn more about your ad choices. Visit podcastchoices.com/adchoices

Gilts rebounded from earlier losses on Monday afternoon, and Novo Nordisk is suing US telehealth company Hims & Hers over ‘knock-off' versions of its weight-loss drugs. Plus, France's central bank chief is stepping down early, and US senators are pushing proposals to lift bank deposit insurance limits to avoid another Silicon Valley Bank debacle. Mentioned in this podcast:Gilts stabilise after cabinet voices support for Keir StarmerNovo Nordisk sues Hims & Hers over copycat weight-loss drugsNovo Nordisk faces more gloom from price cuts in crowded anti-obesity drugs marketFrench central bank governor to step down earlyCan the US crack the formula for ending bank runs?Note: The FT does not use generative AI to voice its podcasts Today's FT News Briefing was hosted and produced by Sonja Hutson. Our show was mixed by Kelly Garry. Additional help from Gavin Kallmann, Michael Lello and David da Silva. Our executive producer is Topher Forhecz. Cheryl Brumley is the FT's Global Head of Audio. The show's theme music is by Metaphor Music.Read a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.

Today's episode features a very special guest, Peter Garnry, CEO and co-founder of Gesda Capital, as we discuss everything from Novo Nordisk's performance in the wake of its Wegovy pill release to nearly everything AI-adjacent, from the market's rough treatment of software-as-a-service names of late to the outlook for Mag7 stocks and hyperscalers on their massive AI capital spending arms race. We also look at the risks of passive investing, discuss the SpaceX IPO and much more. Hosting today's pod is Saxo Global Head of Macro Strategy John J. Hardy. Link: The Acquired podcast episode on Google: The AI Company that we referenced on the podcast.   Two or three times per week, you will also find links discussed on the podcast and a chart-of-the-day over at the John J. Hardy substack. Read daily in-depth market updates from the Saxo Market Call and the Saxo Strategy Team here. Please reach out to us at marketcall@saxobank.com for feedback and questions. Click here to open an account with Saxo. Intro and outro music by AShamaluevMusic DISCLAIMER This content is marketing material. Trading financial instruments carries risks. Always ensure that you understand these risks before trading. This material does not contain investment advice or an encouragement to invest in a particular manner. Historic performance is not a guarantee of future results. The instrument(s) referenced in this content may be issued by a partner, from whom Saxo Bank A/S receives promotional fees, payment or retrocessions. While Saxo may receive compensation from these partnerships, all content is created with the aim of providing clients with valuable information and options.

February 10, 2026: Your daily rundown of health and wellness news, in under 5 minutes. Today's top stories: Apple scraps AI-powered health coach project after delays, concluding it wasn't keeping pace with competitors like Oura, Whoop, and Ultrahuman Oura files patent for AR smart glasses displaying real-time health data controlled through ring-based gestures, positioning itself at center of ambient health tracking Hims & Hers pulls compounded oral GLP-1 pill amid regulatory pressure from HHS and FDA, with Novo Nordisk suing for patent infringement More from Fitt: Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital. Subscribe to our newsletter → insider.fitt.co/subscribe Work with our recruiting firm → https://talent.fitt.co/ Follow us on Instagram → https://www.instagram.com/fittinsider/ Follow us on LinkedIn → linkedin.com/company/fittinsider Reach out → insider@fitt.co  

A.M. Edition for Feb. 9. The latest revelations from the Epstein files bring down the top aide to Britain's Prime Minister. Will Keir Starmer be next? WSJ U.K. correspondent Max Colchester weighs in. Plus, Novo Nordisk shares are rallying after the U.S. Food and Drug Administration threatened to restrict access to the ingredients needed for knockoffs of popular GLP-1 medicines like WeGovy. And SpaceX delays its Mars plans to focus on the Moon instead. Luke Vargas hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Plus: Shares in Novo Nordisk rally after the FDA clamps down on companies making compound versions of weight-loss drug Wegovy. And SpaceX delays a planned Mars mission to focus on Nasa's next moon landing. Daniel Bach hosts. Sign up for WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

National Economic Council Director Kevin Hassett discusses America's economic trajectory, including the jobs market and productivity, inflation, and President Trump's pick for new Fed chair, Kevin Warsh. Direct-to-consumer telehealth Hims & Hers made waves last month when it announced a cheaper, compounded obesity pill similar to Wegovy. Now, after the FDA warned against compounded GLP-1s, Hims & Hers is backing off. Former FDA Commissioner Dr. Scott Gottlieb discusses competition in obesity drugs, Novo Nordisk's lawsuit against Hims & Hers, and the importance of vaccines. Plus, the pharma and AI ads at Super Bowl LX, Japanese Prime Minister Sanae Takaichi secured a supermajority in a snap election, and CNBC's Emily Wilkins reports on the legislative efforts to address the U.S. housing affordability crisis. Emily Wilkins - 10:09Kevin Hassett - 19:21Dr. Scott Gottlieb - 30:10In this episode:Emily Wilkins, @emrwilkinsBecky Quick, @BeckyQuickJoe Kernen, @JoeSquawkAndrew Ross Sorkin, @andrewrsorkinCameron Costa, @CameronCostaNY Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Stocks and crypto coming off another volatile week:Carl Quintanilla, Michael Santoli and David Faber kicked off the hour with a look at the state of the Big Tech trade - as value names like Caterpillar and Walmart power the Dow above 50k for the first time ever. Are AI capex plans still a huge risk for investors? The team discussed whether an early morning rebound for names like Oracle has legs here... and if there's more pain to come in the crypto space, with Bitcoin holding on above $65k. Plus: get a look at the staggering numbers around Super Bowl wagers - and what it could mean for gaming stocks.  Also in focus: the latest out of a growing battle over the future of weightloss drugs - as Novo Nordisk files a new lawsuit against Hims & Hers... and a deep dive on how AI's changing the game for one of America's oldest banks.  Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A landmark US trial begins today in Los Angeles, where plaintiffs say Instagram and YouTube were built to addict kids. We hear from our North America Technololgy Correspondent on what the families said today in court.Then to Japan, where Sanae Takaichi's decisive election win is being read by markets positively - sending the Nikkei to record highs. We'll hear from Tokyo and the US on what her strengthened mandate could mean for the Japan-US relationship. And there's a major pharma-versus-telehealth clash: Novo Nordisk is suing Hims & Hers, accusing it of patent infringement linked to semaglutide - seeking to halt sales of unapproved compounded versions and pursuing damages, in a case that could ripple through the booming online weight-loss market.(Photo: Parents who lost children to alleged social media–related harms hold a vigil ahead of a social media addiction trial in Los Angeles on February 5, 2026. Jill Connelly/Reuters: Reuters).

MRKT Matrix - Monday, February 9th S&P 500 rises, led by tech; Dow climbs to fresh record (CNBC) Alphabet Embarks on Global Bond Spree to Fund Record Spending (Bloomberg) Alphabet Plans Tech's First 100-Year Bond Since Dot-Com Era (Bloomberg) Databricks completes $5 billion funding round at $134 billion valuation (CNBC) Novo Nordisk sues Hims & Hers over copycat versions of Wegovy drugs; Hims stock falls 17% (CNBC) FDA says Novo Nordisk's TV ad for obesity pill includes ‘false or misleading' claims (CNBC) China Urges Banks to Curb Exposure to US Treasuries (Bloomberg) Proposed Ban on Investors in the Housing Market Hits a Wall in Congress (WSJ) Job Hunters Are So Desperate That They're Paying to Get Recruited ⁠(WSJ)⁠ --- Subscribe to our newsletter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://riskreversalmedia.beehiiv.com/subscribe⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ MRKT Matrix by RiskReversal Media is a daily AI powered podcast bringing you the top stories moving financial markets Story curation by RiskReversal, scripts by Perplexity Pro, voice by ElevenLabs

February 6, 2026: Your daily rundown of health and wellness news, in under 5 minutes. Today's top stories: Hims launches compounded GLP-1 pill starting at $49/month as needle-free alternative, but Novo Nordisk threatens legal action over what it calls illegal compounding Women's Health, Sports, and Performance Medical Institute launches with $50M+ to fund injury prevention research for female athletes Peloton reports Q2 revenue of $656.5M missing expectations with paid subscribers down 7% year-over-year, while Brooks reports revenue up 16% marking ninth straight year of growth More from Fitt: Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital. Subscribe to our newsletter → insider.fitt.co/subscribe Work with our recruiting firm → https://talent.fitt.co/ Follow us on Instagram → https://www.instagram.com/fittinsider/ Follow us on LinkedIn → linkedin.com/company/fittinsider Reach out → insider@fitt.co

The U.S. and Iran hold high stakes talks in Oman. Hims & Hers will launch a $49 version of the Wegovy weight loss pill, putting Novo Nordisk under price pressure. Prime Minister Sanae Takaichi is on track to secure an election landside as ‘sanamania' grips Japanese youth. Plus, bigger is better – at least for aerodynamics – as doping chiefs at the Winter Olympics look into claims ski jumpers are injecting their penises to gain a competitive lift. Listen to the Morning Bid podcast ⁠⁠here⁠⁠. Sign up for the Reuters Econ World newsletter ⁠⁠here⁠⁠. Listen to the Reuters Econ World podcast ⁠⁠here⁠⁠. Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt out of targeted advertising. Learn more about your ad choices. Visit megaphone.fm/adchoices

MRKT Matrix - Thursday, February 5th S&P 500 falls for a second day, Nasdaq sheds more than 1% as chip stocks decline, led by AMD ⁠(CNBC)⁠ Software Billionaires Drop $62 Billion in AI-Driven Stock Slump ⁠(Bloomberg)⁠ Software Short Sellers Mint $24 Billion Profit as Stocks Tumble ⁠(Bloomberg)⁠ Nvidia CEO: Software Selloff ‘Most Illogical Thing in the World' ⁠(Bloomberg)⁠ AMD Shares Tumble. Here's Why Earnings Disappointed Investors. ⁠(WSJ)⁠ AMD's Lisa Su says demand for advanced chips is still accelerating, as stock plummets 16% ⁠(CNBC)⁠ Banks seek out new buyers for Oracle data centre loans ⁠(FT)⁠ Bitcoin-Led Crypto Rout Erases Nearly $500 Billion in a Week ⁠(Bloomberg)⁠ Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026 ⁠(CNBC)⁠ Job Growth Probably Cooled Last Month, ADP Data Suggests ⁠(WSJ)⁠ --- Subscribe to our newsletter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://riskreversalmedia.beehiiv.com/subscribe⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ MRKT Matrix by RiskReversal Media is a daily AI powered podcast bringing you the top stories moving financial markets Story curation by RiskReversal, scripts by Perplexity Pro, voice by ElevenLabs

A.M. Edition for Feb. 4. Software stocks are sliding again today, following a rough day on Wall Street that saw the rise of new AI tools shave more than $300 billion off of companies that sell or invest in software. WSJ's Hannah Miao explains what's driving the selloff and what it all means for investors. Plus, Novo Nordisk shares plummet as the weight-loss drugmaker warns of unprecedented pricing pressure. And we look at why China is banning retractable car door handles. Luke Vargas hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

From the BBC World Service: Shares in the Danish pharmaceutical giant Novo Nordisk tumbled 17% on Wednesday after the weight-loss drug pioneer warned of a decline in sales this year amid increasing competition and pressure on prices. Then, the United States renewed an agreement that gives 32 African countries duty-free access to the U.S. market. And later, the prime minister of Spain says he intends to ban social media for children under 16.

Google parent company Alphabet on the move as the tech giant reports results. The details and numbers from their latest quarter, and why tech analyst Gene Munster sees the stock topping the Mag7 group this year. Plus Eli Lilly and Novo Nordisk heading in opposite directions as the weight loss drug race enters its next leg. Why one top health care analyst is flagging management confidence and pricing algorithms as the difference makers.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

From the BBC World Service: Shares in the Danish pharmaceutical giant Novo Nordisk tumbled 17% on Wednesday after the weight-loss drug pioneer warned of a decline in sales this year amid increasing competition and pressure on prices. Then, the United States renewed an agreement that gives 32 African countries duty-free access to the U.S. market. And later, the prime minister of Spain says he intends to ban social media for children under 16.

The US is ramping up efforts to secure its supplies of critical minerals. Vice-president JD Vance has proposed creating a new critical mineral trading bloc to loosen China's control over the sector. The approach could reshape global supply chains for materials essential to electric vehicles, semiconductors and defence systems. Ed Butler finds out more. Shares of Ozempic manufacturer, Novo Nordisk, dropped as nuch as 17% in the face of strong competition. Meanwhile its rival Eli Lilly, is forecasting strong growth. What's the outlook for weight-loss jabs? Elsewhere, the US has renewed an agreement that gives 32 African countries access to the US market. The African Growth and Opportunity Act was allowed to expire last September, after 25 years. It's now been re-authorised until the end of 2026, although Washington has warned it may reshape the deal after that.

The maker of Ozempic says tougher competition from generics in India and China will hit profits this year. Leanna Byrne speaks to its chief financial officer.Plus, Spain moves closer to banning social media for under-16s.And the United States renews a trade deal giving 32 African countries duty-free access to its market.

MRKT Matrix - Wednesday, February 4th S&P 500 falls for a second day, Nasdaq sheds more than 1% as chip stocks decline, led by AMD (CNBC) Software Billionaires Drop $62 Billion in AI-Driven Stock Slump (Bloomberg) Software Short Sellers Mint $24 Billion Profit as Stocks Tumble (Bloomberg) Nvidia CEO: Software Selloff ‘Most Illogical Thing in the World' (Bloomberg) AMD Shares Tumble. Here's Why Earnings Disappointed Investors. (WSJ) AMD's Lisa Su says demand for advanced chips is still accelerating, as stock plummets 16% (CNBC) Banks seek out new buyers for Oracle data centre loans (FT) Bitcoin-Led Crypto Rout Erases Nearly $500 Billion in a Week (Bloomberg) Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026 (CNBC) Job Growth Probably Cooled Last Month, ADP Data Suggests (WSJ) --- Subscribe to our newsletter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://riskreversalmedia.beehiiv.com/subscribe⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ MRKT Matrix by RiskReversal Media is a daily AI powered podcast bringing you the top stories moving financial markets Story curation by RiskReversal, scripts by Perplexity Pro, voice by ElevenLabs

Tech leading today's sell-off, with investors dumping software stocks as the AI revolution threatens the sectors growth model. The names getting hit, and the latest comments from Nvidia CEO Jensen Huang on the company's deal with OpenAI. Plus, AMD and Chipotle report results, Bitcoin's slide continues, and the next move for Novo Nordisk after the stock tanks on a sales warning from the company.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send us a textThis week on On The Pen: The Weekly Dose, we break down Pfizer's $10 billion bet on obesity medicine and whether it's shaping up to be a smart move or a costly miss. We dig into newly released Phase 2b data from Pfizer's once-monthly GLP-1 candidate (formerly Metsera's asset), what the results actually show, and how it stacks up in an increasingly crowded field that includes Novo Nordisk, Eli Lilly, and next-gen combination therapies. We also talk strategy, maintenance dosing, combination GLP-1 + amylin approaches, pricing pressures, cash-pay access, and what this all means for patients navigating a rapidly changing obesity treatment landscape. Plus, earnings week insights, where Pfizer may be headed next, and why pricing and access, not just weight-loss percentages, may end up being the real disruptors.Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

Maria Brinck is a visionary thought leader devoted to breaking up the traditional leadership monopoly in order to generate the “diversity of thought” necessary to solve our most pressing challenges in organizations and nations. Maria founded Zynergy International, a leadership advisory firm in 2013, to fulfill her passion. Today, Maria works with board members, CEOs, executives, business teams and HR professionals and is based in Colorado. Born and raised in Sweden and Algeria, Maria was educated in Sweden, France, and the USA with a focus on International Business. Her most transformative experience, reshaping her worldview, came when she lived and worked with indigenous people in the Congo Basin Rainforest in a remote part of Cameroon. While working on the rehabilitation of chimpanzees and gorillas, she observed first-hand human planetary destruction and its consequences for all living things, but also the type of leadership we need to bring out the best in humanity. Maria is a Gallup-Certified Strengths Coach and holds a CPCC Certification from CTI, and an ACC Certification from ICF, the International Coach Federation. She previously held positions at GE, Eli Lilly & Co, and Novo Nordisk and some of her current clients include Quanex, Astra-Zeneca, Beacon, DaVita, Vizient and Stryker.

很多生技人常感嘆：為什麼我們的技術明明領先，估值卻比不上競爭對手？或者是臨床數據這麼好，為什麼股價不漲反跌？生技業界最神祕的，可能不一定是實驗室裡的獨家配方，而是辦公大樓裡分析師手中的那套財務模型和投資邏輯。我們習慣用專業技術去解讀公司前景，卻經常忽略資本市場如何將『科學可能性』轉換成『商業價值』。 本集《生技來一刻》特別邀請前 J.P. Morgan 分析師 Vincent，從宏觀的生技業界總覽出發，帶我們回溯中國大陸生技業的發展簡史，並探索台灣生技在亞洲與全球資本市場中的可以尋求的定位。與此同時我們也針對當前最火紅的 GLP-1 減重藥市場巨頭（Eli Lilly vs. Novo Nordisk）以及數位醫療商業模式（Teladoc vs. HIMS & Hers）進行了極其硬核的個案分析。這不僅是藥物研發的對抗，更是商業模式與市場滲透策略的頂尖對決。 除了扎實的產業分析，這場訪談更觸及了投資背後的靈魂——決策的藝術。Vincent 將他多年在資本市場修煉的「下注與風險控制」心法，轉化為人人都適用的思考框架。我們深入探討了波動稅務 (volatility tax)的意義和對人生決策的啟發、如何辨識 Type 1 與 Type 2 錯誤、第一印象的重要性、以及通才和專才發展的平衡，讓大家在充滿不確定性的人生賽道上，做出最有價值的選擇。   ✨ 生技來一刻感謝國科會與駐波士頓辦事處科技組贊助我們製作節目。我們也歡迎聽眾小額捐款生技來一刻，您的支持能幫助我們製作更優質的節目。 ✨ 節目連結、講者Linkedin連結請見留言處！感謝講者提供詳盡的延伸閱讀連結和文章！  

GLP-1 drugs like Ozempic and Wegovy are everywhere — but thousands of users now allege the medications caused severe, life-altering injuries including everything from stomach paralysis and colon ruptures to sudden blindness. Drugmakers deny the allegations and say the medications are safe when used as directed. USA TODAY investigative data reporter Austin Fast explains what patients are alleging in court, how widespread GLP-1 use has become and how drug companies like Novo Nordisk and Eli Lilly are responding. Let us know what you think of this episode by sending an email to podcasts@usatoday.com. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

We discussed a few things including:  1. Your career journeys 2. Gitte's biotech venture 3. Garnet's venture capital firm 4. Discuss effects of federal policies on innovation ecosystem 5. Discuss outlook for 2026  Garnet Heraman is a serial entrepreneur and investor with 25 years experience at the intersection of innovation + technology. Originally from the island nation of Trinidad & Tobago, he was educated at Columbia University (BA), NYU (MBA) and The London School of Economics.  As a dotcom entrepreneur Garnet had 3 exits, 1 of which was to a publicly traded company. As an investor, he is co-founder and managing partner of Aperture® Venture Capital, a seed stage fintech fund backed by 7 different Fortune 500 corporations.  He is also an LP in other VC funds such as NY InsurTech Fund II and the Berkeley Skydeck Fund, as well as a prolific angel investor. Garnet is highly sought after as a startup technology expert, appearing in over 30 business publications and at events on 5 continents.  ------ Gitte Pedersen is a scientist, CEO, company builder, and investor with a mission to improve health and sustainability. RNA enthusiast. Focused on helping cancer patients survive through better diagnostics and treatment navigation tools.  Serial entrepreneur. Advised several small and medium-sized biotech companies and the Danish Ministry of Foreign Affairs, bringing in +$1B deals to Danish Biotech companies. Advised the European Commission on evidence-based innovation and investment policies.  Won numerous prizes and awards and raised $8M+ in grants. Worked at Novo Nordisk in several management positions, inventing, developing and bringing multiple products to market worldwide. #podcast #AFewThingsPodcast

Synopsis: From managing a theme park in Canada to leading the U.S. business of one of the world's largest privately held pharma companies, Brian Hilberdink's journey is anything but conventional. Live from JPM 2026 in San Francisco, Biotech 2050 host Alok Tayi sits down with the President, U.S. Human Pharma at Boehringer Ingelheim to explore how frontline sales experience shaped a career now steering launches across obesity, chronic kidney disease, oncology, and rare disease. The pair dive into Boehringer's long-term, privately held model—one that reinvests nearly 30% of revenue into R&D—and the strategic thinking behind its ambitious pipeline: first-in-class breakthroughs in interstitial lung disease, major obesity programs, and upcoming waves of launches through 2027 and beyond. They also unpack the future of commercial pharma—from direct-to-consumer models and digital patient engagement to AI-powered launches and trial recruitment—plus Brian's candid views on China's innovation engine and the growing importance of rare disease. A masterclass in modern pharma leadership, portfolio strategy, and building for generations. Biography: Brian Hilberdink is an accomplished global executive with over 25 years of leadership experience in the pharmaceutical industry, currently serving as President of U.S. Human Pharma at Boehringer Ingelheim. In his role at Boehringer, he oversees several business units across multiple therapeutic areas, including cardiometabolic and renal diseases, obesity, pulmonary fibrosis (ILD), and oncology. Renowned for driving impactful results and fostering cultures of accountability and engagement, Brian consistently enhances organizational performance. Previously, Hilberdink served as Executive Vice President at LEO Pharma, where he led the North American Region and served as President of the U.S. affiliate, which became the primary growth driver for the company globally.. Earlier in his career, Hilberdink held several senior-level positions at Novo Nordisk, where he worked across multiple geographies. He was recognized for developing and executing innovative go-to-market strategies, resulting in the successful launch of multiple blockbuster therapies in the areas of obesity and diabetes.

In this episode, Bethanie Stein, PharmD, Segment President of Pharmacy at Humana, discusses how employers are approaching GLP-1 coverage and why partnerships with manufacturers like Eli Lilly and Novo Nordisk matter now. She shares how CenterWell Pharmacy is using transparency, clinical oversight, and adherence focused models to expand access while managing costs.

This episode covers: Cardiology This Week: A concise summary of recent studies What´s new in TAVI?  Digital solutions in arrhythmias Mythbusters - Gratitude is heart healthy Host: Emer Joyce Guests: JP Carpenter, Davide Capodanno, Fleur Tjong Want to watch that episode? Go to: https://esc365.escardio.org/event/2528 Want to watch that extended interview on Digital solutions in arrhythmias, go to: https://esc365.escardio.org/event/2528?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson. Fleur Tjong has declared to have potential conflicts of interest to report: Amsterdam UMC Innovation grant, Heath Holland TKI, Abbott, Dutch Research Council, Boston Scientific.

Host: Emer Joyce Guest: Fleur Tjong Want to watch that extended interview on https://esc365.escardio.org/event/2528?resource=interview Go to: Want to watch that episode? Go to: https://esc365.escardio.org/event/2528 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson. Fleur Tjong has declared to have potential conflicts of interest to report: Amsterdam UMC Innovation grant, Heath Holland TKI, Abbott, Dutch Research Council, Boston Scientific.

The Food and Drug Administration on recently approved a pill version of Wegovy, Novo Nordisk's blockbuster weight loss drug. The Wegovy pill, as it's called, is first oral version of a GLP-1 drug that has been brought to market for weight loss. A second pill, from Eli Lilly, is also expected to be approved in the coming months. Nicolette M. Pace, a Registered Dietician, Chef, & Nutritionist, is here to talk about all this and more!

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Philipp Vetter über neue Hoffnung bei Novo Nordisk, Quanten-Angst beim Bitcoin und einen Erfolg für Bayer. Außerdem geht es um Micron, Worthington Steel, Klöckner & Co., Eli Lilly, Viking Therapeutics, Meta, Alphabet, Microsoft, Amazon, BMW, Maersk, Legrand, Nvidia, Tesla, den iShares MSCI World Energy Sector (WKN: A2PHCF), den Xtrackers MSCI World Energy (WKN: A113FF), den VanEck Uranium and Nuclear Technologies (WKN: A3D47K), den Xtrackers FTSE Vietnam Swap ETF (WKN: DBX1AG) und den VanEck Vietnam ETF (WKN: A2AHKE). Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Why are investors buzzing about Novo Nordisk's Wegovy pill launch? And how has sentiment turned against software makers like Salesforce? Plus, what drove BlackRock's asset pile to a record $14 trillion? Host Jack Pitcher discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Why are investors buzzing about Novo Nordisk's Wegovy pill launch? And how has sentiment turned against software makers like Salesforce? Plus, what drove BlackRock's asset pile to a record $14 trillion? Host Jack Pitcher discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Market update for January 16, 2026Follow us on Instagram (@TheRundownDaily) for bonus content and instant reactions.In Today's Episode:Zaid quoted in the WSJ: “he just has aura”Eli Lilly and Novo Nordisk hit with antitrust lawsuitNetflix expands its Sony Pictures deal and pushes further into video podcastsEnergy stocks slide after the White House unveils a plan to stop power bills from going upFun fact of the day: Wall Street banks posted a record $134 billion in trading revenue (while still cutting thousands of jobs)

At the 2025 Medical Innovation Olympics, a powerful all-star expert panel moderated by Melissa Norcross (Vice President, Corporate Strategy, Hyland Software) featuring Eddie Power (CEO, Empower Medical, former Global Medical Affairs Leader at Pfizer), Vivek Mukhatyar (Senior Director, Medical AI Team Lead, Pfizer), and Ravi Kiran Koppichetti (Senior Analyst, Manufacturing Technology, Vertex; former Lead IT Data Engineer, Novo Nordisk) cut through the hype and delivered a practical playbook for leaders in healthcare: 1) Fall in love with the problem, not the tool; 2) Think in systems, not silos; and 3) Train your people, not just your models.Timeline00:00 Highlight 1: Why AI Innovation Fails When the Problem Is Mis-framed01:20 Highlight 2: Probable vs Precise Decisions: Where AI Helps vs Where Governance Must Lead03:38 Highlight 3: Falling in Love with the Problem, Not the Solution04:38 Highlight 4: Non-Patient AI Use Cases: Process, Partnership & Proof06:00 Leadership in the Age of AI: Framing the Right Questions08:52 Systems Thinking in Healthcare Innovation (Hepatitis C Case Study)11:35 Constraints in Medical Affairs: Where Humans Must Stay in the Loop13:19 AI as “Intelligence on Tap” vs Clinical Decision Authority17:53 Defining Target Conditions and What “Done” Really Means20:15 Systems Failures in Real-World Healthcare Environments22:50 How Providers, Payers, and Pharma Are Using AI Today25:47 Who Decides: Human vs AI Agents in Regulated Healthcare27:18 Industry 4.0 Explained: Integrating OT and IT in Pharma Manufacturing30:33 Data Quality, Trust, and Why Most Organizational Data Is Unstructured32:03 Probabilistic AI vs Precision Decisions: A Leadership Framework34:35 Trust, Evaluations, and Human-in-the-Loop AI Design39:11 Why 95% of AI Pilots Fail — and the Role of AI Ambassadors43:08 Closing Reflections: Systems Thinking, Learning Loops, and Fearless Curiosity

One in four people have fatty liver disease... and most don't even know it. In this powerful episode of My Weight Live, Dr. Joshi breaks down who should be screened, how liver health and weight are connected, the early warning signs, the treatments available and the simple lifestyle changes that can lead to better health.This podcast was sponsored by Novo Nordisk Canada. It was created independently by My Weight - What to Know with no influence from Novo Nordisk.The medical information in My Weight - What to Know's content is provided as an information resource only. The content is not in any way intended to be nor should you rely on it as a substitute for professional medical evaluation, diagnosis, advice or treatment.All content of this channel is owned by What To Know, LLC. and is protected by worldwide copyright laws. You may download content only for your personal use (i.e., for non-commercial purposes) but no modification or further reproduction of the content is permitted. The content may otherwise not be copied or used in any way.My Weight - What to Know ©️ 2026

Broadcast from KSQD, Santa Cruz on 1-08-2026: Dr. Dawn concludes her 2025 medical advances recap, noting that while GLP-1 weight loss drugs showed unexpected benefits for addiction, schizophrenia, and dementia risk, Novo Nordisk recently reported semaglutide had no effect on cognition in people with existing dementia or mild cognitive impairment. She describes the first successful human bladder transplant performed on May 4th. The 41-year-old recipient received both kidney and bladder due to the bladder's complex blood vessel network. Surgeons practiced on cadavers with active circulation before achieving success, opening pathways for future bladder-only transplants for the 84,000 Americans diagnosed with bladder cancer annually. An emailer follows up about purslane for cognitive health. Dr. Dawn reviewed the referenced studies and found neither actually supported claims about purslane and cognition—one discussed the Lyon Heart Study's Mediterranean diet, the other described antioxidant properties. She cautions listeners that websites citing "scientifically proven" claims often reference articles that don't support their assertions. An emailer asks about statin alternatives after developing severe muscle pain on both atorvastatin and rosuvastatin. Dr. Dawn suggests he shouldn't be on statins given his classic adverse reaction. She recommends ezetimibe plus oat bran for cholesterol, metformin for his elevated triglycerides indicating insulin resistance, and checking LDL particle size and inflammation markers. She emphasizes that cholesterol is a risk factor, not a disease, and treating 50 low-risk people for 10 years prevents only one heart attack. A caller discusses plaque formation theory, comparing it to calluses. Dr. Dawn explains Linus Pauling's similar hypothesis that plaque forms at vessel bifurcations to protect against turbulent blood flow damage. She warns against driving total cholesterol below 130, as it disrupts steroid hormone production. The caller shares his mother's near-fatal rhabdomyolysis from statins—muscle breakdown releasing myoglobin that clogs kidneys—and criticizes data transfer failures between hospital systems. An emailer reports four UTIs in two months at age 79. Dr. Dawn questions whether all were true infections, since vaginal contamination causes false positives on dipstick tests. For confirmed UTIs, she recommends D-mannose and cranberry to prevent bacterial adhesion, post-void residual ultrasound to check for incomplete emptying, lactobacillus probiotics, and vaginal DHEA (Intrarosa) to restore mucosal thickness and disease resistance. Dr. Dawn describes Stanford's Phase III trial for dystrophic epidermolysis bullosa, where defective collagen-7 causes skin layers to separate at the slightest touch. Researchers take patient skin biopsies, use retroviruses to insert corrected genes, grow credit-card-sized skin grafts over 25 days, then suture them onto wounds. At 48 weeks, 65% of treated wounds fully healed versus 7% of controls. She reports a Stanford study showing premature babies who heard recordings of their mothers reading for 2 hours 40 minutes daily developed more mature white matter in language pathways. The left arcuate fasciculus showed greater development than controls, demonstrating how early auditory stimulation shapes brain circuitry even in NICU settings. Dr. Dawn concludes with tattoo safety concerns. Modern vivid inks contain compounds developed for car paint and printer toner, including azo dyes that break down into carcinogenic aromatic amines—especially during laser removal. Pigment particles migrate to lymph nodes and persist in macrophages, causing prolonged inflammation. She advises those with tattoos to avoid laser removal, wear sunscreen, practice lymphatic hygiene, and reconsider extensive new tattoos.

In this episode of the Dividend Talk podcast, we review the performance of their Community Dividend Growth Portfolio, discuss Novo Nordisk's news, the Rio Tinto & Glencore Merger, Terry Smiths Fundsmith annual shareholder letter, and much more.And as always, they answer many questions from the community.

Plus: Andreessen Horowitz raises over $15 billion across several funds. And LG Electronics expects to post a quarterly operating loss for the first time since 2016. Julie Chang hosts. Learn more about your ad choices. Visit megaphone.fm/adchoices

Carl Quintanilla, Jim Cramer and David Faber led off the show with market reaction to the December employment report: Non-farm jobs growth came in lower than expected, up 50,000. The unemployment rate fell to 4.4%. National Economic Council Director Kevin Hassett joined the program with White House reaction to the results. The anchors and Hassett discussed him being in the running for Fed chair, the Supreme Court's upcoming decision on tariffs and what to expect from President Trump's Friday meeting with oil CEOs about reviving production in Venezuela. Also in focus: The stocks surging on Meta's nuclear deals, Amazon's pharmacy to offer Novo Nordisk's Wegovy pill.Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

We kicked off the program with four news stories and different guests on the stories we think you need to know about!The unsolved murder of Gail Miles…Watertown’s 1st Black police officer.Guest: Emily Sweeney – Boston Globe Cold Case Files reporter Why do most people fail to keep financial resolutions every year? How to reprogram your money mindset and stop wasting your hard-earned cash!Guest: Dr. Willie Jolley - award-winning speaker and best-selling author - here to discuss his new book, Rich Is Good, Wealthy Is Better! Homeowner Side Hustle: Americans Turning Backyards Into Big Bucks w/ Tiny-Home or ADU (accessory dwelling unit). Why are so many people interested in Tiny Homes and how are they making money off of them?Guest: Jon Grishpul – Co-CEO of MaxableSpace.com The approval of the first weight loss pill…FDA approves Wegovy weight loss pill from Novo Nordisk. What to know…Guest: Dr. Richard Siegel - Co-director of the Diabetes and Lipid Center at Tufts Medical Center & Endocrinologist at Tufts Medicine Weight + Wellness – StonehamSee omnystudio.com/listener for privacy information.

Asia Bureau Chief Jing Yang joins TITV Host Akash Pasricha to discuss exclusive reporting on DeepSeek's new V4 flagship model and its superior coding capabilities. We also talk with Cory Weinberg about Strava's confidential IPO and Lambda's $350M raise, and Every CEO Dan Shipper about how AI is blurring the lines between media and software. Then, Ro CEO Zach Reitano breaks down the launch of a new GLP-1 pill with Novo Nordisk and AI's role in modern healthcare. Lastly, we dive into the Silicon Valley obsession with biological age with Jemima McEvoy and the AI shopping race with Editors Martin Peers and Meredith Mazzilli.Articles discussed on this episode: https://www.theinformation.com/articles/deepseek-release-next-flagship-ai-model-strong-coding-abilityhttps://www.theinformation.com/articles/silicon-valley-obsessed-biological-age-tests-despite-dubious-sciencehttps://www.theinformation.com/articles/nvidia-backed-cloud-provider-lambda-talks-raise-350-million-ahead-ipohttps://www.theinformation.com/articles/strava-filed-confidentially-ipo-hired-goldman-sachsTITV airs on YouTube, X and LinkedIn at 10AM PT / 1PM ET. Or check us out wherever you get your podcasts.Subscribe to: - The Information on YouTube: https://www.youtube.com/@theinformation- The Information: https://www.theinformation.com/subscribe_hSign up for the AI Agenda newsletter: https://www.theinformation.com/features/ai-agenda

January 8, 2026: Your daily rundown of health and wellness news, in under 5 minutes. Today's top stories: Trump administration releases new dietary guidelines backed by HHS Secretary RFK Jr., recommending avoidance of ultra-processed foods and added sugars while endorsing red meat and full-fat dairy Eli Health unveils instant saliva-based tests for testosterone and progesterone at $8 per test, with results in minutes and Q1 rollout ahead Mark Mastrov and LongRange Capital reacquire 24 Hour Fitness, with plans to upgrade clubs for strength and recovery while preparing for international growth Smart ring shipments jumped 50% in 2025, outpacing smartwatches as Oura explores digital IDs and payments beyond health tracking Novo Nordisk's Wegovy pill launches nationwide as first oral GLP-1 for weight loss at $149/month through pharmacies and telehealth providers More from Fitt: Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital. Subscribe to our newsletter → insider.fitt.co/subscribe Work with our recruiting firm → https://talent.fitt.co/ Follow us on Instagram → https://www.instagram.com/fittinsider/ Follow us on LinkedIn → linkedin.com/company/fittinsider Reach out → insider@fitt.co

Do you suffer from Proctalgia fugax?Today is National Pass Gas Day! - https://nationaltoday.com/national-pass-gas-day/First GLP-1 pill for obesity from Novo Nordisk launches in the U.S. - https://www.cnbc.com/2026/01/05/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-us.html‘Delco Pooper' ordered to undergo anger management and do community service - https://www.nbcphiladelphia.com/news/local/delco-pooper-senteneced/4320774/Follow The Rizzuto Show Daily Comedy Show → https://linktr.ee/rizzshowConnect online → https://1057thepoint.com/RizzShowHear The Rizz Show daily on the radio at 105.7 The Point | Hubbard Radio in St. Louis, MO See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In recent years, we have seen tremendous growth not just in the popularity of anti-obesity medications, but also in the medications themselves, how effective they are, how many there are. What exactly has changed during this rapid evolution? How safe and effective are these medications today? What challenges still exist in using them? To help answer these questions, host Aaron Lohr speaks with Gitanjali Srivastava, MD, professor of medicine, medical director of Vanderbilt Obesity Medicine, and founding program director of the Obesity Medicine Fellowship at Vanderbilt University Medical Center. Dr. Srivastava presented at the Endocrine Society’s Obesity Fellows Conference in September 2025. The title of her presentation was “Pharmacological Approaches to Treating and Understanding Complicated Obesity.” Listening to this episode can earn you 0.5 ABIM MOC points and 0.5 AMA PRA Category 1 credits. If you are interested in those points and credits, you will need to take a pre-test on the Endocrine Society Center for Learning before listening to this episode. You can find a link in this episode’s show notes. After that pre-test, listen to this episode in the Center for Learning, then take the post-test. This episode is made possible by educational grants from Lilly and Novo Nordisk. Show notes are available at https://www.endocrine.org/podcast/enp109 — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

This episode opens the year with one of the most consequential—and complicated—weeks in GLP-1 obesity medicine. We break down three stories that, taken together, reveal why patients are increasingly reading past headlines and demanding accountability from the industry. First, we examine early-phase trial data from Arrowhead Pharmaceuticals, after headlines claimed its experimental INHBE-targeting therapy “nearly doubled” the weight loss of Zepbound. We walk through what the data actually showed, why the comparison was misleading, how trial design and dosing matter, and why Phase 1 results should never be treated as superiority claims. Next, we turn to a major access milestone: the official launch of oral Wegovy, the first FDA-approved GLP-1 pill for obesity from Novo Nordisk. We discuss how this pill differs from compounded oral semaglutide, why its pricing strategy is so disruptive, and what this launch means for people who have avoided injectable medications. We also explore how direct-to-consumer access, telehealth partnerships, and retail pharmacy distribution signal a broader shift in how obesity care is being delivered. Finally, we address the most ironic—and uncomfortable—story of the week: manufacturing quality concerns involving branded Wegovy pens, reported to include biological particulate matter, at the same time Novo Nordisk continues a years-long public and legal campaign against compounded GLP-1 medications on safety grounds. We discuss FDA inspection history, the acquisition of Catalent, and why credibility depends on consistency—especially when millions of patients are paying close attention. This episode isn't anti-pharma or pharma-friendly. It's patient-first. And it asks a simple question: Who do we trust when science, marketing, access, and manufacturing all collide at once? Episode Timestamps 00:00 — Why this first episode of 2026 matters 02:10 — Hair found in Wegovy pens and why patients notice hypocrisy 06:15 — Arrowhead trial headlines vs. what the data actually shows 11:40 — Why tirzepatide dosing and trial design matter 17:30 — What INHBE targeting may actually be good for (and what it's not) 21:45 — Sponsor: SHED and access pathways for obesity care 25:10 — Oral Wegovy officially launches: what's different this time 30:20 — How the Wegovy pill works and why bioavailability matters 35:40 — Pricing, telehealth, Costco, and direct-to-consumer access 41:50 — Why pills lower barriers for millions of patients 46:10 — Manufacturing quality, Catalent, and FDA citations 52:30 — Why safety arguments against compounding are being scrutinized 58:40 — Zooming out: access, accountability, and patient trust 1:02:00 — Final thoughts and what to watch next Topics Covered GLP-1 trial hype vs. real-world context Phase 1 data limitations and headline inflation Tirzepatide dosing and misleading comparisons Oral Wegovy vs. compounded oral semaglutide GLP-1 pill pricing and insurance implications Direct-to-consumer pharma and telehealth disruption Manufacturing quality and FDA oversight Compounding pharmacies and healthcare system resilience Patient trust, transparency, and credibility in obesity medicine Useful Links & Resources On The Pen Links & Advocacy: https://otplinks.com Sponsor – SHED (use code OTP25): https://tryshed.com FDA Drug Safety & Recalls: https://www.fda.gov/drugs Follow On The Pen: YouTube: https://youtube.com/@onthepen Substack: https://onthepen.substack.com Support the Show If this episode helped you better understand what's really happening in obesity medicine: Leave a 5-star rating and review Hit Subscribe so you don't miss future episodes Join us live Mondays, Wednesdays, and Fridays at 12pm Eastern on YouTube Patients deserve clarity. That's what we're here for. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this special live AI edition of the Learning & Development Podcast, David James brings together Egle Vinauskaite, Ross Stevenson, and Peter Manniche Riber for a candid, practical conversation about what AI really means for L&D today. The discussion explores the gap between hype and reality, the tools and applications that are starting to make a meaningful difference and how AI is already being used to improve performance, capability, and skills development. The panel examines what L&D teams are getting right, where major opportunities are being missed and the challenges slowing progress, from security and capability constraints to mindset and organisational conservatism. They also look ahead to how AI could reshape the way L&D operates and how the function is perceived across the business. A clear, grounded and insight-rich conversation for L&D professionals wanting to understand where AI can drive genuine value. KEY TAKEAWAYS AI frees up time and has the capabilities to enable L&D to move beyond courses into solving business problems and improving performance and capability. Real-world examples are shared. AI strategy can't sit with L&D alone; a multidisciplinary, business-driven group must shape it. To stay relevant, L&D needs commercial acumen and tech curiosity, alongside human strengths like storytelling, influence, and relationship‑building. BEST MOMENTS “Too many are just bolting AI onto an existing model, rather than stepping back and saying, does that model still serve us today? ” “We know that content does not equal skills.” “What we really need to do is to target effectiveness. We need to solve the problem.” Egle Vinauskaite Egle Vinauskaite is a learning, behaviour, and technology specialist who works with global enterprises and emerging edtech innovators. With a background across AI, XR, mobile learning, and digital platforms, she brings a sharp perspective on how technology is reshaping organisational learning and the future of work. As both advisor and researcher, she helps L&D teams integrate AI into their operations and equip workforces with the skills needed for effective adoption. https://www.linkedin.com/in/vinauskaite http://nodes.works The Race for Impact report: https://donaldhtaylor.co.uk/research_base/focus04-race-for-impact Ross Stevenson Ross is a leading voice in the global L&D community, known for his practical, no-nonsense approach to modern learning. Through his writing, speaking and community platform Steal These Thoughts, he explores how organisations can better align learning with performance, develop essential skills, and embrace new technologies - including AI. Ross brings a strategic yet pragmatic perspective on how L&D teams can evolve and remain relevant in an age of rapid technological change. https://www.linkedin.com/in/rstevensonuk www.stealthesethoughts.com Peter Manniche Riber Peter is an experienced L&D leader who until recently served as Head of New Tech, Digital Learning Solutions at Novo Nordisk, transforming HR and learning for a global workforce of 70,000+. Passionate about using technology to simplify and enhance learning, he experiments with generative AI, machine learning, adaptive platforms, and data-driven methods to deliver timely, effective solutions. With a strong foundation in team leadership and human-centric design, Peter helps organisations solve business challenges through technology while driving meaningful collaboration and measurable impact. https://www.linkedin.com/in/petermannicheriber RESOURCES L&D Master Class Series: https://360learning.com/blog/l-and-d-masterclass-home HOST CONTACT https://twitter.com/davidinlearning https://www.linkedin.com/in/davidjameslinkedin https://360learning.com/the-l-and-d-collective This Podcast has been brought to you by Disruptive Media. https://disruptivemedia.co.uk/

Looking at a weird GDP data point. Calling BS on Russia/Ukraine peace talks. Gold and Silver – WOW! Closing out the year – a good one too! PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter Warm-Up - CTP Cup - All systems go! 9 participants! - Lots to be excited about and anxious too - Looking at a weird GDP data point - Calling BS on Russia/Ukraine peace talks Markets - Gold and Silver - WOW! - Closing out the year - a good one too! - Buyers are still hot to buy any dip - "Diet" pills coming Bitters Making Progress  - Chocolate -Dark Cherry -Infusions - https://highdesertbotanicals.com NYE Celebration - Cities across America ring in the new year by dropping unexpected objects: - Amelia Island, FL drops a giant shrimp. - Nashville drops a 400lb musical note with 28,140 LEDs. - Boise, ID, drops a glowing potato. - Key West, FL, drops an eight-foot ruby-red heel—complete with a drag queen inside! - In Spain, revelers gulp down 12 grapes—one for each midnight chime—to bring luck for each month - Denmark - Danes toss old dishes at friends' doors—large piles of broken crockery at dawn are seen as tokens of good luck. What a year! - So many themes in 12 months - AI, Tariffs, War and Trade War, Fat drugs, Deglobalization - Data centers, semiconductors, and supporting infrastructure like power and cooling systems. - Approx: DJIA +13.5%, SP500 +17%, NASDA +21%, BTCUSD -7.6%, Gold +64%, SLV +145%, $DXY -9.5%, EEM +30% - 2026 - Opportunities and Auld Lang Xiety (Tech still looks frothy in certain names) Top New Year's Resolutions - Exercise More - Eat Healthier - Save More Money/Get Out of Debt - Be Happy/Improve Mental Health - Lose Weight - Spend More Time with Family & Friends - Learn a New Skill/Hobby - Get Organized Active Management (Funds) - Same report annually - A small group of tech super stocks accounted for an outsize share of returns in 2025, extending a pattern in place for the better part of a decade. - Around $1 trillion was pulled from active equity mutual funds over the year, marking an 11th year of net outflows, while passive equity exchange-traded funds got more than $600 billion. - The concentration of gains in a few stocks made it harder for active managers to do well, with 73% of equity mutual funds trailing their benchmarks this year, the fourth most in data going back to 2007. - BUT, there are some areas that it makes sense for active management ---- Equity vs Fixed income and reasoning --- Efficient markets, boots on the ground Fat Pill - The FDA has approved the first-ever GLP-1 pill from Wegovy maker Novo Nordisk. - Novo Nordisk said the starting dose of 1.5 milligrams will be available in early January in pharmacies and via select telehealth providers with savings offers for $149 per month. - The approval gives Novo Nordisk a head start over chief rival Eli Lilly, which is racing to launch its own obesity pill. - Packaged food makers and fast-food restaurants may be forced to overhaul more of their products next year as newly approved, appetite-suppressing GLP-1 pills become available in January PowerBall - A ticket sold in Arkansas scored a $1.8 billion Powerball jackpot after Wednesday night's draw — one of the richest lottery prizes in U.S. history, landing just in time for Christmas. - The payout soared after last Monday's drawing produced no winners, with last-minute ticket sales pushing the jackpot to $1.817 billion. That makes it the second-largest U.S. lottery prize ever and the biggest Powerball of 2025, the lottery website said on Thursday. - The winning numbers — 4, 25, 31, 52, 59 and the Powerball 19 - Odds: one in 292.2 million. Silver - Amazing year! - Sunday night futures - >$83 then turned hard lower| - Down 7% on Monday - Range $83 - $71 (15%) for the day - Some rumors about a bank collapse due to wrong way position on Silver - forced liquidation and covering.... ----- Hard to believe that a bank was short that much silver - but..... SoKo Breach - South Korean online retail giant Coupang said it will offer 1.69 trillion South Korean won ($1.17 billion) in compensation to 34 million users affected by a massive data breach disclosed last month. - That is about 4% of Coupang's annual revenue - but a big chunk of their profit - $34 per user NVDA Deal - Nvidia has yet to issue a public announcement or disclosure regarding its $20 billion Groq deal that CNBC was first to cover on Wednesday. - Groq described the deal as a “non-exclusive licensing agreement,” a tool that's been used by tech giants of late in part to avoid regulatory scrutiny. - Analyst: “Antitrust would seem to be the primary risk here, though structuring the deal as a non-exclusive license may keep the fiction of competition alive,” Bernstein's Stacy Rasgon wrote in a report. - Groq will remain an independent company (?) GDP Consumption - Something is a bit off.... - With the marketplace costs increasing, this may be more than a one-off expenditure Q3 GDP Surge Russia/Ukraine - Less that an hour after the White House claimed great movement toward peace - Russian President Putin told President Trump that Russia will revise its negotiating position, raising questions over prospects for peace deal - Russian Foreign Minister Sergei Lavrov says Ukraine tried to attack Russian President Putin's residence - Does anyone even listen to the crap coming out of the White House anymore? - Did you hear Lutnick trying to explain the 600% reduction in costs for pharmaceuticals? Math wizards! - - For 2026, my wish is that they continue to work on the job at hand and just shut up Just for fun - Who is biggest drinker of spirits? - While there's no single official "heaviest drinker," legendary wrestler Andre the Giant is widely cited as having unmatched capacity, famously downing 119 beers in one sitting (or even up to 156 in other accounts) Oil - Crude oil futures down about 9.5% YTD - Much of the drop due to pick up in production (supply/demand) - Still a floor with as Russia, Nigeria, Venezuela etc - What will it take to move up? Best Auto Stock for 2025? - GM! Better than ford, Tesla and others (up 55%) - best year from coming out of bankruptcy in 2009 - Ford up 35% - Mary Barra, CEO selling into the strength - $73 M sold this year (Position down 73% from what she held last year) - - - Barra has contended for years that stock undervalued. With all of these say what does that say now? --- Would she ever say shares are overvalued? More fun stats - A peer?reviewed 2025 study estimates AI data centers (including indirect usage from electricity generation) consumed 312–765 billion liters of water annually. That's more than all bottled water consumed worldwide each year - Direct (on-site) water is used for cooling servers via systems like cooling towers or liquid loops. Indirect (off-site) water stems from electricity generation—particularly from thermal and nuclear plants, which require significant cooling resources - ??? Estimates suggest a single standard AI prompt (about 100 words) is linked to around 1.5 liters of water—accounting for the entire chain of consumption. (This is total usage from cooling powr consumption, electricity generation) - Global AI workloads consumed 50–60 terawatt-hours (TWh) in 2025—roughly the annual electricity use of a medium-sized country like Switzerland. - By 2030, AI-related electricity demand could reach 300–500 TWh annually, according to energy analysts—comparable to the entire electricity consumption of countries like France. Over to Iran - President Trump tells reporters that if Iran is building up its nuclear program, the U.S. will have to "knock them down" again --- Wait - I thought we destroyed all of their nuke aspirations??? - - - AND - Iran's currency hit a record low, triggering wave of protests, according to Bloomberg Fed News - Top Fed Chair Candidate Odds Narrow Again, With Hassett at 43% and Warsh at 35% - President Trump still angry at Powell 0threating to sue for incompetence Odd - Tesla Inc. published a series of sales estimates indicating the outlook for its vehicle deliveries may be lower than many investors were expecting. - The carmaker posted estimates showing analysts on average expect the company to deliver 422,850 cars in the fourth quarter, down 15% from a year earlier. - Tesla is on course for its second consecutive drop in annual vehicle sales, with the company compiling an average estimate for 1.6 million deliveries, down more than 8% from a year earlier. - These are estimates published by analysts - Tesla put on its own site - WHY? End of Year Stat - The U.S. national debt is climbing at a rapid pace and has shown no signs of slowing down despite the growing criticism of massive levels of government spending. - The national debt, which measures what the U.S. owes its creditors, rose to $38,386,384,190,622.68 as of Dec. 30, according to the latest numbers published by the Treasury Department. - That is an increase of about $5.8 billion daily - ~$18 per person in the US per day increase ($7,300) - or about the monthly price of leasing a small Mercedes - Each person in US owes approx $128,000 Love the Show? Then how about a Donation? THE CLOSEST TO THE PIN 2025 Winners will be getting great stuff like the new "OFFICIAL" DHUnplugged Shirt! CTP CUP 2025 Participants: Jim Beaver Mike Kazmierczak Joe Metzger Ken Degel David Martin Dean Wormell Neil Larion Mary Lou Schwarzer Eric Harvey (2024 Winner) FED AND CRYPTO LIMERICKS See this week's stock picks HERE Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter